Moderna CEO Stéphane Bancel on the first-ever positive Phase 3 results for an individualized mRNA cancer vaccine: "After working 10 years on an individualized treatment against cancer using mRNA technology, the Phase 3 was positive. It's the first time that there is an agent in melanoma that is better than Keytruda alone." "It's the first time there is a cancer vaccine working. The field has been doing that for 20-plus years, I think more than 1,000 clinical trials that have all failed." "We met the primary endpoint of the study, which was recurrence-free survival... And then, to our own surprise, because this was the first interim analysis... we met the secondary endpoint, which was distant metastasis-free survival." @JorgeCondeBio @moderna_tx(a16z)